KemPharm Reports Positive Results from Trial

KemPharm has reported positive results from a study to assess KP511 Active Pharmaceutical Ingredient (API) compared to equivalent doses of hydromorphone hydrochloride (HM API).

KP511 is KemPharm’s investigational prodrug of hydromorphone to treat pain. The company said that KP511 demonstrated statistically significant reduction in peak and overall hydromorphone exposure with KP511 API versus HM API.

“This study provides very strong preliminary evidence that KP511 imparts significant potential for deterring intranasal abuse when compared to currently marketed hydromorphone products,” said Lynn Webster of PRA Health Sciences, after an independent review of the study results.

Leave a Comment